Dr. Guy Boivin is a professor in the Department of Microbiology-Immunology and Infectious Diseases of the Faculty of Medicine at Laval University. He holds the Canada Research Chair in Emerging Viruses and Antiviral Resistance, as well as a “Foundation” grant from the Canadian Institutes of Health Research (CIHR). He is also co-principal investigator of major grants, such as the FPQIS ($ 12M), for the development of new generation influenza vaccine in the elderly.

Dr. Boivin is the author or co-author of 300 scientific publications and 350 presentations at various international conferences and symposia. He has also contributed to the creation of 9 patents and is co-founder of the company Signia Therapeutics, specializing in the repositioning of drugs to counter viral respiratory infections. He is also the director of an NC3 laboratory that will be operational in 2018, which will expand the various research projects to highly pathogenic respiratory viruses, such as avian influenza viruses (H5N1, H7N9) and other emerging respiratory viruses. (MERS-CoV).

His research program focuses on the diagnosis, pathogenesis, and treatment of viral infections. He studies herpetic and respiratory viruses, including those causing the flu (including avian flu). More recently, he has also been interested in the Zika virus. He uses cell and molecular biology technologies, as well as different animal models to develop rapid diagnostic tests, evaluate new antiviral molecules, elucidate mechanisms of resistance to antiviral agents, and generate new vaccines. He has developed several multicenter studies to assess the clinical and epidemiological impact of emerging respiratory viruses. He collaborates with several fundamental and clinical research groups as well as various pharmaceutical companies. His work will have a significant impact on the diagnosis, treatment, and prevention of frequent and potentially life-threatening viral infections in certain groups of individuals.

CHUL
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 47762
+1 418-654-2715
guy.boivin@crchudequebec....

Latest news

268 entries « ‹ 1 of 27 › »

Gravel A, Dubuc I, Wallaschek N, Gilbert-Girard S, Collin V, Hall-Sedlak R, Jerome KR, Mori Y, Carbonneau J, Boivin G, Kaufer BB, Flamand L

Cell Culture Systems To Study Human Herpesvirus 6A/B Chromosomal Integration.

Journal Article

J Virol, 91 (14), 2017, ISSN: 0022-538X.

Abstract | Links:

Zarrouk K, Piret J, Boivin G

Herpesvirus DNA polymerases: Structures, functions and inhibitors.

Journal Article

Virus Res, 234 , pp. 177-192, 2017, ISSN: 0168-1702.

Abstract | Links:

Menasria R, Canivet C, Piret J, Gosselin J, Boivin G

Protective role of CX3CR1 signalling in resident cells of the central nervous system during experimental herpes simplex virus encephalitis.

Journal Article

J Gen Virol, 98 (3), pp. 447-460, 2017, ISSN: 0022-1317.

Abstract | Links:

Abed Y, Carbonneau J, L'Huillier AG, Kaiser L, Boivin G

Droplet digital PCR to investigate quasi-species at codons 119 and 275 of the A(H1N1)pdm09 neuraminidase during zanamivir and oseltamivir therapies.

Journal Article

J Med Virol, 89 (4), pp. 737-741, 2017, ISSN: 0146-6615.

Abstract | Links:

Tu V, Abed Y, Barbeau X, Carbonneau J, Fage C, Lague P, Boivin G

The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.

Journal Article

Antiviral Res, 137 , pp. 6-13, 2017, ISSN: 0166-3542.

Abstract | Links:

Stephen P, Baz M, Boivin G, Lin SX

Structural Insight into NS5 of Zika Virus Leading to the Discovery of MTase Inhibitors.

Journal Article

J Am Chem Soc, 138 (50), pp. 16212-16215, 2016, ISSN: 0002-7863.

Abstract | Links:

Ann J, Abed Y, Beaulieu E, Bouhy X, Joly MH, Dube K, Carbonneau J, Hamelin ME, Mallett C, Boivin G

Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets.

Journal Article

Influenza Other Respir Viruses, 10 (2), pp. 122-6, 2016, ISSN: 1750-2640.

Abstract | Links:

Zacour M, Ward BJ, Brewer A, Tang P, Boivin G, Li Y, Warhuus M, McNeil SA, LeBlanc JJ, Hatchette TF

Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories.

Journal Article

Clin Vaccine Immunol, 23 (3), pp. 236-42, 2016, ISSN: 1556-6811.

Abstract | Links:

Drouot E, Piret J, Boivin G

Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus.

Journal Article

Antivir Ther, 21 (6), pp. 535-539, 2016, ISSN: 1359-6535.

Abstract | Links:

Abed Y, Bouhy X, L'Huillier AG, Rheaume C, Pizzorno A, Retamal M, Fage C, Dube K, Joly MH, Beaulieu E, Mallett C, Kaiser L, Boivin G

The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models.

Journal Article

Antiviral Res, 132 , pp. 6-12, 2016, ISSN: 0166-3542.

Abstract | Links:

268 entries « ‹ 1 of 27 › »
Signaler des ajouts ou des modifications

Active projects

  • A research program on the pathogenesis, treatment and prevention of respiratory and herpes viruses, Subvention, Instituts de recherche en santé du Canada, Subventions Fondation, from 2016-07-01 to 2023-06-30
  • Canadian Immunization Research Network, Subvention, Instituts de recherche en santé du Canada, Réseau canadien de recherche sur l’immunisation, from 2014-06-01 to 2021-12-31
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche en infectiologie, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2024-11-06
  • How to better manage infectious diseases in ER by triage with molecular mini-panels for the rapid detection of highly transmissible pathogens, Subvention, Consortium québécois sur la découverte du médicament, from 2018-10-01 to 2022-09-30
  • Innovative therapeutic approaches for the 2019-novel coronavirus, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement : Possibilité de financement canadienne pour une intervention de recherche rapide contre la maladie à coronavirus 2019 (COVID-19), from 2020-02-01 to 2022-01-31
  • Sentinel surveillance, viral shedding, clinical characteristics and outcomes of confirmed and suspected hospitalized cases of COVID-19/SARS-CoV-2 infection in the Canadian Immunization Research Network (CIRN), Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement : Possibilité de financement pour une intervention de recherche rapide contre la COVID-19, from 2020-04-01 to 2021-03-31
  • Sex as a Biological Variable Supplement - Innovative therapeutic approaches for the 2019-novel coronavirus, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement : Financement supplémentaire pour l’intégration du sexe comme variable biologique dans l’intervention de recherche rapide contre la COVID-19, from 2020-05-01 to 2021-03-31

Recently finished projects

  • Chaire de recherche du Canada sur les virus en émergence et la résistance aux antiviraux, Subvention, Secrétariat des Chaires de recherche du Canada, Chaires de recherche du Canada - Fonctionnement, from 2013-07-01 to 2020-06-30
Data provided by the Université Laval research projects registery